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Abstract
Background Psoriasis patients carry an increased risk for associated comorbidities. Dermatologists have to be aware
of the effects of systemic treatments not only on psoriasis but also on co-occurring diseases. In case of other coexisting
inflammatory diseases, the right psoriasis treatment may improve both disorders. For infectious and malignant disorders,
some treatments have to be avoided as they may be harmful.
Objective The primary objective of this project was to collect evidence for the creation of practice guidelines for sys-
temic treatment of psoriasis (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis).
Methods Evidence-based recommendations were formulated using a quasi-Delphi methodology after a systematic
search of the literature and a consensus procedure involving eight psoriasis experts.
Results Recommendations are given on the use of systemic treatment in psoriatic arthritis, inflammatory bowel dis-
ease, demyelinating disorders, hepatitis B and C, HIV and cancer.
Conclusion This expert opinion is a practical guide for dermatologists when handling psoriasis patients with these
specific conditions.
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Introduction
Psoriasis is associated with several other diseases which may or
may not share pathogenic similarities. Coexisting disorders
should be taken into account when initiating a systemic treat-
ment. The most common associated disorder is psoriatic arthritis
which may be present in up to 25% of psoriasis patients.1 Unfor-
tunately, not all treatments are equally effective for both joints
and skin requiring dermatologic-rheumatologic team work.
Inflammatory bowel disease is more prevalent in psoriasis
patients. A meta-analysis found a relative risk in patients with
psoriasis for Crohn’s disease and ulcerative colitis of 2.53 and
1.71, respectively.2 TNF-blockers have become one of the
cornerstones of the management of inflammatory bowel disease.
More recently, the IL-12/23 pathway has also been targeted.
Encouraging results have been obtained with ustekinumab
blocking both IL12 and IL23, while monoclonal antibodies
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targeting only IL23 are also promising and entering phase II and
III trials.3 In contrast, IL-17 blockade is ineffective in Crohn’s
disease and may cause disease exacerbations.4,5 Anti-IL-17 treat-
ment was linked to a nearly 3-fold increase of IBD in patients
with chronic inflammatory diseases indicating that patients at
risk for IBD should be identified in advance.6
Studies investigating a link between psoriasis and demyelinat-
ing diseases such as multiple sclerosis and Guillain–Barre are
inconsistent and conflicting. While some small studies and case
reports have suggested an increased risk, larger studies were
unable to confirm this finding.7 The role of TNF in demyelinat-
ing disorders is yet incompletely understood, and several cases
developing multiple sclerosis and Guillain–Barre in patients
receiving TNF-blockers have been reported.7
As psoriasis requires a long-term treatment, patients with a
history of malignancy or developing cancer during systemic pso-
riasis treatment are a relatively frequent event. Psoriasis patients
carry an increased risk for different types of cancer and cancer
mortality especially from liver, oesophageal and pancreatic can-
cer and lymphoma.8 In general, both conventional and newer
treatments for psoriasis do not seem to result in a marked
increased rate of malignancy.9 Nonetheless, in cancer patients the
preservation of an effective antitumoral response is crucial and in
general exceeds the importance of clearing the skin disease. Simi-
larly in hepatitis or HIV, systemic treatments may worsen the
infectious load and cause drug–drug interactions with antiviral
treatments. In this article, practice guidelines for managing psori-
asis patients with these coexisting disorders are proposed.
Material and methods
For the methodology, we refer to Part 1 of the BETA-PSO pro-
ject. In Part 2, each expert was again assigned a separate topic to
summarize based on a systematic search of the literature in
PubMed. Articles (including RCTs, case–control studies, obser-
vational studies, systematic reviews, meta-analyses, case reports
but excluding letters and opinion papers) on psoriasis patients
treated with systemic treatments for psoriasis (conventional,
synthetic and biological) were included that reported data on:
1 Coexisting inflammatory conditions such as psoriatic arthri-
tis and inflammatory bowel disease
2 Chronic infections like HIV, hepatitis or tuberculosis
3 Specific neurological conditions like demyelinating disease
4 The influence of the treatment on malignancies (including
new-onset malignancies during/after treatment or treatment
in patients with previous malignancies)
The definition of recommendations (strong vs. weak; in favour
or against) was adapted compared to Part 1 and was different in
the group of coexisting inflammatory diseases compared to infec-
tious/malignant disorders. In inflammatory diseases, a weak rec-
ommendation in favour was considered in case the drug might be
beneficial for the inflammatory disorder. In contrast, a weak rec-
ommendation in favour in case of infectious or malignant
disorders was assigned in case the drug is (likely) not beneficial
but also not harmful for the infection or malignancy.
Results
Clinical recommendations
Psoriatic arthritis (PSA) Several different classes of biological
and non-biological drugs including TNFa antagonists, ustek-
inumab, IL17 inhibitors, as well as some non-biologic and con-
ventional drugs, are licensed both to treat psoriasis and psoriatic
arthritis (PSA).
In psoriasis patients with psoriatic arthritis, we recommend
methotrexate, apremilast and the following biological drugs: adali-
mumab, certolizumab pegol, etanercept and infliximab; ustek-
inumab; secukinumab and ixekizumab.10 They are not only effective
in treating psoriasis but also alleviate the symptoms of PSA.
It is our expert opinion that other biologics including guselk-
umab, risankizumab, tildrakizumab and brodalumab are also
effective treatment in psoriatic patients with PSA, although they
are currently unlicensed in this indication.11
Systemic treatment with cyclosporine, for psoriasis patients
with PSA, is less advisable due to limited evidence. Nonetheless,
some studies support beneficial effects of cyclosporine on the
symptoms of PSA in patients with skin psoriasis.12,13 We do not
recommend using the conventional drugs acitretin and fuma-
rates in psoriasis patients with PSA as they are not indicated for
the treatment of PSA. One study showed improvement of PSA
with fumarates although confirmatory data are missing.14 There
is no clinical or theoretical evidence to support benefit of PSA
using acitretin.
Inflammatory bowel disease (IBD) Inactive IBD. In psoriasis
patients with inactive IBD, we recommend that the TNF antago-
nists: adalimumab, certolizumab pegol and infliximab; the IL12/23
inhibitor: ustekinumab; the IL23/p19 inhibitors: guselkumab, risan-
kizumab and tildrakizumab; as well as the synthetic drug apremi-
last, and the conventional drugs, methotrexate, cyclosporine,
fumarates and acitretin, can all be used as systemic treatments as
they also have a beneficial or neutral effect on IBD symptoms.15–17
We advise caution with use of the following anti-IL17 biologi-
cal drugs: secukinumab, ixekizumab and brodalumab, to treat
psoriasis patients with inactive IBD, and in those patients with a
family history of IBD.6 We also advise not using etanercept in
these patients due to the possibility of a flare-up of IBD symp-
toms.18
Active IBD. We recommend the following systemic biological
drugs are used to treat psoriasis patients who also have active
inflammatory bowel disease (IBD): adalimumab and infliximab.
This is because these TNFa antagonists are licensed for the treat-
ment of both psoriasis and inflammatory bowel disease.15 We
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also advise the use of certolizumab pegol as it is beneficial in
these patients despite not being licensed for IBD in Europe.19
The IL12/23 inhibitor, ustekinumab, is also licensed for both
the treatment of psoriasis and IBD. We note that a significantly
higher dose is necessary to achieve an adequate response for IBD
symptoms.16,20
Expert opinion exists that methotrexate and cyclosporine are
somewhat effective and can be used if necessary. Apremilast
showed efficacy in a phase II study for ulcerative colitis.21
We recommend against the use of biological drugs: etaner-
cept, secukinumab, ixekizumab and brodalumab, to treat psoria-
sis patients with active IBD, due to the risk of exacerbations of
IBD with their use.22,23
Demyelinating diseases (MS/Guillain–Barre syndrome) Multi-
ple sclerosis (MS) is an immune-mediated demyelinating disease
of the central nervous system that affects approximately 1/1000
people in Belgium. The incidence and prevalence of psoriasis are
higher in the MS population than in a matched cohort from the
general population.24
Many of the available systemic biological and non-biological
drugs may be used to treat psoriasis patients with demyelinating
diseases such as MS or Guillain–Barre Syndrome, although sup-
porting data are limited.
In psoriasis patients with demyelinating diseases such as
MS, we recommend that the conventional drug dimethylfu-
marate is used as first-line therapy. This is because fumarates
are indicated in psoriasis and in MS.24 We also recommend
the IL12/23 inhibitor: ustekinumab due to data from the
ACCEPT study supporting its use in psoriasis patients with
concomitant MS.25
There is limited data supporting IL17 inhibitors: ixekizumab
and secukinumab; there is some evidence to suggest that secuk-
inumab may reduce MRI lesion activity in these patients.26 Aci-
tretin may also be used as systemic treatment for psoriasis
patients with MS or Guillain–Barre Syndrome.27,28 It is also our
opinion that methotrexate is effective in the treatment of psoria-
sis patients with MS, but it is off-label in this indication.29,30
We advise colleagues not to use the anti-TNFa drug class, due
to development of MS or worsening of pre-existing disease. We
recommend against using adalimumab, certolizumab pegol,
etanercept and infliximab in these patients. Discontinuation of
the drug should be considered if any of these disorders develop
or there is worsening of pre-existing disease.31–35 Indeed, there is
evidence to suggest a higher risk of peripheral neuropathy in
patients with rheumatic diseases who are past users of TNF-in-
hibitors.36
Chronic infections
Human immunodeficiency virus (HIV) HIV with undetectable
viral load. It is a real challenge to manage already
immunocompromised HIV+ patients with psoriasis. Most cur-
rently available systemic therapies for psoriasis are immunosup-
pressive, which poses a distinct clinical problem. We
recommend that the opinion of infectious disease colleagues on
the best approach to manage the already immunocompromised
HIV+ patient with psoriasis is gained per case.
We recommend that either acitretin or apremilast is used first
line in HIV+ patients. In our opinion, acitretin and apremilast
are weak immunosuppressive drugs, and so the infection risk is
not substantially increased with treatment.37,38
It is our opinion that the TNF antagonists: adalimumab, cer-
tolizumab pegol, etanercept and infliximab; the IL12/23 inhibi-
tor: ustekinumab; the IL23/p19 inhibitors: guselkumab,
risankizumab and tildrakizumab; the IL17 receptor blocker: bro-
dalumab; the IL17 inhibitors: ixekizumab and secukinumab, can
all be used as systemic treatments for HIV+ psoriasis with unde-
tectable viral load undergoing highly active antiretroviral therapy
(HAART). These agents may even have positive effects on CD4+
counts and viral load.39
We advise against using some of the conventional drugs
including methotrexate, cyclosporine and fumarates in these
patients, due to their immunosuppressive effect and potential
adverse drug–drug interactions with HAART although these
data are limited.40,41 Drug interactions should also be checked
before starting apremilast, especially with CYP3A4 inducers.42
HIV with detectable viral load. We recommend gaining advise of
infectious disease colleagues on the best approach to manage the
already immunocompromised HIV+ patient with psoriasis.
From a safety perspective, we recommend using the non-bio-
logics, apremilast and acitretin, in HIV+ psoriasis patients with a
detectable viral load. This is due to the good safety profile of
these drugs on CD4+ T-lymphocyte count and HIV viral load in
these patients.37,38 However, we also note that supporting data
are limited. Other treatments should be case by case discussed
with an infectious disease specialist. We discourage the use of
methotrexate, cyclosporine and fumarates in HIV patients with
detectable viral load.
Hepatitis C From a safety perspective, many of the biological
drugs and some non-biological drugs available in Belgium (and
listed below) can be used to treat those psoriasis patients who
also have chronic hepatitis C infection, with minimal risk of viral
reactivation. This advice is based on the European PSONET
health insurance registry data.43
In psoriasis patients with chronic hepatitis C infection, it is
our opinion that the following biological drugs, adalimumab
and etanercept, are effective and well-tolerated short-term treat-
ments in these patients. There are less data available supporting
the use of infliximab and certolizumab pegol.44,45 There is also
limited data supporting the use of the IL12/23 inhibitor ustek-
inumab, and the IL17 inhibitors secukinumab and
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ixekizumab.46,47 Results from the first active comparator
(ACCEPT) study of psoriasis biologic agents comparing ustek-
inumab and the TNF antagonist etanercept demonstrated that it
is more appropriate to use etanercept rather than ustekinumab
in psoriasis patients with hepatitis C infection.48
We note a lack of data with the other IL23/p19 inhibitors:
guselkumab, risankizumab and tildrakizumab; and the IL17
receptor blocker: brodalumab, and with the synthetic drug
apremilast, in these patients.48
We advise caution with the conventional drug, cyclosporine
due to its strong immunosuppressive activity and reports of
hepatotoxicity and liver injury with its use.49 Although these
data are conflicting, we note that methotrexate is contra-indi-
cated in these patients and so do not recommend its use in
these patients. This advice is also extended to acitretin in these
patients.40,50,51
As there is potential risk of viral reactivation in psoriasis
patients with chronic hepatitis C infection, we do recommend
joint follow-up with hepatology colleagues together with close
monitoring of liver tests and viral titres. A positive serology may
suggest a risk of viral reactivation, and antiviral prophylaxis may
be required.52 In most countries, hepatitis C treatment is present
and leads to full eradication. In that case, no further follow-up is
needed.
Hepatitis B Similar to those patients with hepatitis C co-infec-
tion, from a safety perspective, most of the biological drugs and
some non-biological drugs available in Belgium can be used with
caution to treat psoriasis patients who also have chronic hepati-
tis B infection, with minimal risk of viral reactivation.
In psoriasis patients with chronic hepatitis B infection, it is
our opinion that the biological drug ustekinumab and the con-
ventional drugs, acitretin and cyclosporine as well as apremilast
can be used with caution as systemic psoriasis therapy – in terms
of hepatitis B infection risk. Data from two large clinical trials
also show that the risk of hepatitis B infection is similar with or
without apremilast treatment.46,53 The only reports from reacti-
vation of hepatitis B with cyclosporin are from severe immuno-
suppressed patients.54 Reactivation of hepatitis B occurred in
39% of HBsAg+ patients treated with TFN-a-blockers for
autoimmune diseases but not in HBsAg-/anti-HBc+ patients.55
We note that methotrexate is contra-indicated in these
patients, due to significant risk of reactivation of hepatitis B with
a potentially fatal outcome and so advise against its use.40 Some
studies have also shown that the systemic biologics such as TNF
antagonists may cause reactivation of hepatitis B and also with
anti-IL17, secukinumab, treatment.50,52,56 We therefore advise
that psoriasis patients who are HBV carriers are closely moni-
tored for hepatitis B reactivation. If hepatitis B reactivation
occurs, then antiviral prophylaxis should be given concomitantly
in consultation with infectious disease colleagues and as advised
by the manufacturers.
Latent tuberculosis There is an increased risk of reactivation
of latent TB infection with some immunosuppressant therapies.
From a safety perspective, many of the biological and non-
biological drugs available in Belgium to treat patients with
psoriasis can be used to treat those patients who also have
latent TB.
In psoriasis patients with latent TB, the IL17 inhibitors: ixek-
izumab and secukinumab; the IL23 inhibitors guselkumab, til-
drakizumab and risankizumab as well as synthetic non-
biological drugs, such as apremilast, and conventional drugs,
such as acitretin and fumarates, may be used as systemic treat-
ments. Caution is advised for methotrexate and cyclosporine.
Given the critical role of TNF-a in granuloma formation, we
advise also caution with use of the TNFa antagonists: adali-
mumab, certolizumab pegol, etanercept and infliximab as data
suggest an increased risk of reactivation of latent TB infection
with their use.57 This risk seems less so with the IL12/23 inhibi-
tor: ustekinumab although cases of reactivation have been
reported due to the inhibition of the critical IL-12 pathway in
the regulation of immunity toM. tuberculosis.58–60
For the IL23/p19 inhibitors: guselkumab, risankizumab and
tildrakizumab; the IL17 receptor blocker: brodalumab; the IL17
inhibitors: ixekizumab and secukinumab, no increased risk for
TB reactivation has yet been reported.61–64
We also note that TB testing is no longer mandatory from a
scientific point of view (but is still present as a reimbursement
criterion) for IL17 and IL23 antagonists, as well as with apremi-
last and acitretin. We note however that there are limited data
available with the IL12/23 inhibitor: ustekinumab; the IL23/p19
inhibitors: guselkumab, risankizumab and tildrakizumab; the
IL17 receptor blocker: brodalumab in these patients.
There are now some data available to suggest that the IL17
inhibitors (secukinumab and ixekizumab) may be better toler-
ated regarding latent TB reactivation risk compared with the
TNFa and IL-12/23 antagonists in psoriasis patients with TB.62
Likewise, there are also some data to suggest that etanercept may
be a better treatment option than adalimumab in these patients,
although the evidence is limited.65
Tuberculosis, including reactivation and new onset, has been
reported in some patients receiving biological treatments.
Therefore, we recommend that before initiation of biologicals
of the anti-TNFa or anti-IL12/23 class or in case of anticipated
long-term immunosuppressive treatment with conventional
drugs, patients must be tested for both active and inactive
(‘latent’) tuberculosis infection. If latent TB is diagnosed,
appropriate treatment with anti-tuberculosis prophylaxis must
be started before initiation of the treatment and continued for
1 month before starting the systemic psoriasis treatments. We
advise that patients are monitored closely for TB infection
before, during and after treatment with the systemic biological
drugs, as these drugs may take several months to be eliminated
(SmPCs).
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Malignancies/cancer
Solid cancer Patients with psoriasis have a slight increase in
the relative risk of developing solid organ malignancies, which
increases with the severity of psoriasis.66 Therefore, careful con-
sideration must be given to the systemic treatment of psoriasis
patients with a history of a solid cancer.
From a safety perspective, we recommend that the following
biological drugs, adalimumab, certolizumab pegol, etanercept,
and infliximab and ustekinumab, as well as the following con-
ventional drugs, methotrexate, fumarates and acitretin, and the
synthetic drug apremilast, can be used as systemic treatments for
psoriasis patients with a history of a solid cancer.9 We do advise
that there is no need for waiting before commencing systemic
treatment with acitretin, fumarates, methotrexate in psoriasis
patients with a history of a solid cancer. However, we advise
consulting with oncology colleagues before commencing treat-
ment.
We recommend waiting 5 years before starting biological
therapy in psoriasis patients with a history of a solid cancer in
accordance with BAD guidelines.67 However, to the best of our
knowledge there is no definitive evidence to demonstrate that
these drugs, when used as monotherapy for the treatment of
psoriasis, increase the risk of (recurrence of) malignancy. We
therefore suggest that clinicians consult with oncology colleagues
on a case-by-case basis, taking into consideration the stage,
whether a cancer has been treated effectively and prognosis of
the patient’s tumour before commencing treatment.
The conventional drug cyclosporine has tumour-promoting
effects, and in the SmPC, a higher risk for lymphoma and other
malignancies, especially skin malignancies, is mentioned.41,68
Therefore, it is also to be used with caution.
We advise caution with use of the synthetic drug
apremilast, in psoriasis patients with a history of a solid
cancer, due to insufficient long-term safety data being
available although this drug has limited immunosuppressive
properties.69,70 It is therefore less likely to impair antitu-
moral immunity.
We advise caution with the use of the anti-IL17 drugs, bro-
dalumab, ixekizumab and secukinumab, and the anti-IL23
drugs, guselkumab, risankizumab and tildrakizumab, due to
insufficient long-term safety data being available. Nonetheless,
the IL23 and IL17 drugs are less likely to be involved in antitu-
moral immunity as they do not impair the Th1 response.
Haematological cancer Patients with psoriasis have a moder-
ate increase in the relative risk of developing haematological
malignancies, in particular, lymphoma, but the absolute risk
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*Unlicensed for this indication.
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remains very low.66 Therefore, from a safety perspective we
recommend that the following conventional systemic drugs,
methotrexate, fumarates and acitretin, are used as first-line
treatment of psoriasis patients with a history of haematologi-
cal malignancies. We also advise that apremilast is often a
good treatment option for these patients, based on our
Table 2 Recommendations for the use of systemic psoriasis treatment according to coexisting infectious or malignant disorders
Strong recommendation 
in favour
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clinical opinion, even though there is limited long-term
(3 years now) safety data available.
For second-line treatment, we advise that the biological drug,
ustekinumab, may be used. Insufficient data are present on the
new IL-17 and IL-23 blockers.
We note that it is recommended to wait 5 years before com-
mencing treatment with biological drugs in these patients.67
However, we advise consulting with onco-haematology col-
leagues before commencing treatment. The decision should be
made on a case-by-case basis, taking into consideration the stage
and prognosis of the patient’s tumour before commencing treat-
ment.
Skin cancer Non-melanoma skin cancer. The risk of non-me-
lanoma skin cancer (NMSC) increases with age and severity of
psoriasis, although contradictory findings exist.71,72 From a safety
perspective for those psoriasis patients with a history of skin can-
cer, we advise the conventional drugs, methotrexate, fumarates
and acitretin, may be used as systemic treatment. Since acitretin is
likely to be protective against a variety of solid and haematologi-
cal malignancies, including cutaneous squamous cell carcinoma,
we advise that acitretin can be used in combination with these
other systemic drugs and at a lower dose according to the thera-
peutic result.73–75 From a safety perspective, we also recommend
that the biological IL12/23 inhibitor, ustekinumab, may be used
in the systemic treatment of psoriasis patients with a history of
non-melanoma skin cancers.76 We also advise that the synthetic
drug apremilast can be used in these patients as no safety signal
has yet been identified. Nonetheless, data are limited.
For the more clinically important cutaneous squamous cell
carcinoma (SCC), we advise that the anti-TNFa biological drugs,
adalimumab, certolizumab pegol, etanercept and infliximab and
the conventional drugs methotrexate and cyclosporine, are con-
tra-indicated in psoriasis patients with aggressive or invasive
SCC. This is because the risk of SCC is increased in psoriasis and
an increased risk has also been reported with these drugs. How-
ever, we note that well-differentiated and in situ lesions do not
constitute a contraindication, and these drugs are not contra-
indicated in psoriasis patients with a history of basal cell carci-
noma (BCC). There is no contraindication for patients with
BCC although an alternative therapy can be considered.
We advise caution with the newer anti-IL17 drugs, ixek-
izumab, secukinumab and IL-17 receptor blocker brodalumab
and the IL23 inhibitors, guselkumab, risankizumab and tildrak-
izumab due to insufficient clinical follow-up data. However, as
these newer drugs do not target the Th1 pathway and IL-17 has
been shown to induce skin cancer cell proliferation there is cur-
rently no theoretical ground suggesting an increased risk of skin
cancer with these treatments.77
However, we wish to emphasize that reduction in common
risk factors such as sun exposure or phototherapy (in particular
PUVA) has a much greater effect on reducing cancer burden in
patients with psoriasis than stopping or avoiding systemic
immune modulatory agents.66
Table 3 Evidence of systemic treatments for psoriasis in different clinical conditions
ACITR CYCLO MTX FUM APR IFX ETA ADA CERT USTE GUS RIS TIL SECU IXE BROD
PsA peripheral B A A C A A A A A A A A B A A A
PsA spine B A A NA A A A A A A A A NA A A A
PsA enthesitis/dactylitis B A A NA A A A A A A A A B A A A
Inactive IBD C C A C C A C A A A C A C C C C
Active IBD C C A NA C A A A A A C A C A A A
HIV active B C C C C C C C C C C C C C C C
HIV non-active B B B A B B B B B B B B B B B B
Chronic Hep C C B B C C B B B B C C C C C C C
Chronic Hep B B B A NA B B B B B B NA NA NA B C C
Latent TB B C C NA A A A A A C C C C C C C
Demyelinating disease C B B A NA A A A A A NA NA NA C NA NA
Cancer C A B NA C B B B B B NA NA NA NA NA NA
Levels of evidence: A (high level of evidence: randomized clinical trials, extensive experience in clinical practice), B (moderate level of evidence: observational
studies, limited randomized clinical trials, moderate experience in clinical practice), C (very low level of evidence: case series, retrospective without controls,
low experience in clinical practice).
Results of the studies: (i) Green: preserved efficacy without increased adverse events or worsening of the comorbidity; (ii) Yellow: limited risk of decreased
efficacy and/or limited risk of increased adverse events or worsening of the comorbidity, (iii) Orange: moderate risk of decreased efficacy and/or moderate risk
of increased adverse events or worsening of the comorbidity, (iv) Red: important risk of decreased efficacy and/or moderate risk of increased adverse events
or worsening of the comorbidity.
ACIT, acitretin; ADA, adalimumab; APR, apremilast; BROD, brodalumab; CERT, certolizumab pegol; CYCLO, cyclosporin; ETA, etanercept; GUS, guselku-
mab; IFX, infliximab; IXE, ixekizumab; RIS, risankizumab; SEC, secukinumab; TIL, tildrakizumab; UST, ustekinumab.
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Melanoma. Interestingly, the risk for melanoma in patients with
psoriasis may be lower than in individuals without psoriasis.66
In psoriasis patients with a history of melanoma, we recommend
using the conventional drugs, acitretin, fumarates and
methotrexate, as systemic therapy.78–81
When using the anti-TNFa drugs, adalimumab, certolizumab
pegol, etanercept, and infliximab, and the IL-12/23 inhibitor,
ustekinumab, we note that the BAD guidelines recommend wait-
ing for 5 years before starting these biological therapies in psori-
asis patients with a history of melanomas.67 Exposure to TNFa
inhibitors has been linked to an increased development of mela-
noma, and cases with metastatic melanoma under TNFa inhibi-
tion have been reported.82–84 To date, an increased risk for
melanoma has not been confirmed for ustekinumab.85 Data for
other IL-23 inhibitors, IL-17 inhibitors or IL-17 receptor blocker
are limited.86 The recurrence of melanoma has been described in
one patient receiving apremilast.87
We suggest that clinicians consult with oncology colleagues
on a case-by-case basis and take into consideration the stage and
prognosis of the patient’s tumour.
Discussion
Creating practice guidelines (BETA-PSO) to treat psoriasis
patients with comorbidities is complex as new treatments are
being introduced which have limited available data in subgroups
of patients with specific comorbidities. The evidence used to
make our recommendations is summarized in Tables 1, 2 and 3.
Fortunately, most psoriasis drugs have a well-documented
efficacy in psoriasis arthritis.
The obvious caveats are to prescribe TNF-a blockers in patients
with tuberculosis and multiple sclerosis or IL-17 blockers in
patients with inflammatory bowel disease. Practising dermatolo-
gists should be encouraged to gather a thorough medical history
which includes the family medical history (e.g. relatives with
IBD). In patients with cancer or hepatitis/HIV infection, broad
immunosuppressants and targeted treatments affecting the Th1
response should be avoided. An exception seems to be ustek-
inumab which despite its IL-12 inhibiting capacity carries only a
relative contraindication in non-active HIV infection and
cancer.85
Anti-IL17 blockers and receptor blockers, anti-IL23 antibod-
ies and acitretin are in theory believed to exhibit no to very lim-
ited impairment of antiviral and antitumoral responses although
more long-term data are needed.88 Studies on fumarates are for
several comorbidities limited or lacking. Apremilast seems to
have limited immunosuppressive properties and is considered a
safe option in most high-risk patients although its efficacy in
psoriasis is less impressive compared to the newest biologics.
We believe this BETA-PSO project offers a valuable contribu-
tion facilitating a well-informed decision to initiate systemic
treatment in complex psoriasis patients. Given the rapid evolu-
tion of the therapeutic landscape of psoriasis, readers should be
aware that this project is a living guideline that will require a reg-
ular update based on new data.
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